WSJ
14 Sept 2026, 06:02 UTC · 4h ago
AstraZeneca Breast-Cancer Drug Misses Goal in Late-Stage Trial
Verdict
Headline leans bearish. One claim average +0.80.
Score contradicts the headline.
Claims average
+0.80
−1 bearish0bullish +1
More positive than 98% of claims this week
Price reaction
No single ticker to price — this story's claims are scored on their own.
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen
